The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines

Anti-Cancer Drugs

Volumn 15, Issue 1, 2004, Pages 71-77

  Kim, J Y ^a,b   Patterson, A V ^c   Stratford, I J ^c   Hendry, J H ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b National Cancer Center   (South Korea)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bioreductive agent; DT diaphorase; Hypoxia; RH1

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 REDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RH 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

AEROBIOSIS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BENZOQUINONES; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; NAD(P)H DEHYDROGENASE (QUINONE); NADPH-FERRIHEMOPROTEIN REDUCTASE; SPECTROPHOTOMETRY; TRANSFECTION; TRIAZINES;

EID: 4344611719     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200401000-00011     Document Type: Article

References (24)

1. Gurney H, de Campos ES, Dodwell D, Kamthan A, Thatcher N. Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. Eur J Cancer 1991; 27:565-568.
2. Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, Wientjes MG, et al. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity and human bladder tumors. Clin Cancer Res 2001; 7:1313-1319.
3. Wang X, Doherty G, Leith M, Curphey T, Begleiter A. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer 1999; 80:1223-1230.
4. Marshall RS, Rauth AM. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res 1988; 48:5655-5659.
5. Rauth AM, Mohindra JK, Tannock IF. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res 1983; 43:4154-4158.
6. Winski SL, Hargreaves RH, Butler J, Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res 1998; 4:3083-3088.
7. Winski SS, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 2001; 61:1509-1516.
8. Kim JY, West C, Valentine H, Ward T, Patterson A, Stratford I, et al. Evaluation of the bioreductive agent RH1 as a potential radiosensitiser. Radiother Oncol 2003; in press.
9. Wu K, Eng E, Knox R, Chen S. Demonstration of the activation of prodrug CB1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model. Arch Biochem Biophys 2001; 385:203-208.
10. Patterson A, Saunders M, Chinje E, Talbot D, Harris AL, Stratford IJ. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR4233) and RSU 1069. Br J Cancer 1997; 76:1338-1347.
11. Cowen RL, Patterson AV, Telfer BA, Airley R, Hobbs S, Phillips RM, et al. Viral delivery of P450 reductase recapitulates the ability of constitutive Overexpression of reductive enzymes to potentiate the activity of Mitomycin C in human breast cancer xenografts. Mol Cancer Therap 2003; in press.
12. Hobbs S, Jitrapakdee S, Wallace J. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1 alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 1998; 252:368-372.
13. Hoff M, Christoffels V, Labruyere W, Moorman A, Lamers W. Electrotransfection with 'intracellular' buffer. Methods Mol Biol 1994; 48:185-197.
14. Ernster L. DT-diaphorase. Methods Enzymol 1967; 10:309-317.
15. Masters BSS, Williams CH, Kamin H. The preparation and properties of microsomal TPNH-cytochrome creductase from pig liver. Methods Enzymol 1967; 10:565-573.
16. Malkinson AM, Siegel D, Forrest GL, Gazdar GF, Oie HK, Chan DC, et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to Mitomycin-D. Cancer Res 1992; 52:4752-4757.
17. Smitskamp-Wilms E, Giaccone G, Pinedo H, Laan B, Peters G. DT-diaphorase activity in normal and neoplastic human tissues: an indicator for sensitivity to bioreductive agents? Br J Cancer 1995; 72:917-921.
18. Adams GE, Stratford IJ. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Phys 1994; 29:231-238.
19. Robertson N, Haigh A, Adams G, Stratford I. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 1994; 30A:1013-1019.
20. Saunders M, Patterson A, Chinje E, Harris A, Stratford I. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer 2000; 82:561-656.
21. Patterson A, Barham H, Chinje EC, Adams G, Harris AL, Stratford IJ. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR3233). Br J Cancer 1995; 72:1144-1150.
22. Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ. P450 reductase activates tirapazamine to restore oxic and hypoxic cytotoxicity in a resistant derivative of the A549 lung cancer cell line. Br J Cancer 1999; 82:651-656.
23. Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P450) reductase. Proc Natl Acad Sci USA 1996; 93:456-460.
24. Brown J, Siim B. Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 1996; 6:22-36.